Algorithms of gastroesophageal reflux disease treatment


Cite item

Full Text

Abstract

Gastroesophageal reflux disease (GERD) is a chronic, relapsing disease, caused by the disturbances of motor and evacuator functions of gastroesophageal zone, characterized by spontaneous and regularly regurgitation of gastric and/or duodenum content to esophagus, with specific symptoms which not depends on morphologic changes of esophagus mucosa. According to Genvald guidelines GERD is divided on endoscopic-negative GERD, endoscopic-positive GERD and Barrett esophagus. Treatment depends on the disease form. Artile includes the modern algorithms of GERD management. The most effective drugs for GERD treatment are proton pomp inhibitors.

References

  1. Dent J, Brun J, Fendrick A, et al. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1999;44(Suppl. 2):S1-16.
  2. Рациональная фармакотерапия заболевании органов пищеварения / Под ред. В.T. Ивашкина. М., 2003.
  3. Talley N, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. Aliment Pharmacol Ther 2001;15:347-54.
  4. Holtmann G. The clinical usefulness of PPIs: Are they all the some? (Yes) "PPIs: Are they all the some? - The Ultimate Debate". 10 UEGW, Absrtact Book. Geneva 2002;10-11.
  5. Bell NJV, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-esophageal reflux disease. Digestion 1992;51(Suppl. 1):59-67.
  6. Sachs G, et al. Synthesis or rupture: duration of acid inhibition by proton pump inhibitors. Drugs Today 2003;39 (Suppl A):11-4.
  7. Pilotto A, Franceschi M., Leandro G. Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients. World J Gastroenterol 2007;13(33):4467-72.
  8. Naumburger A, Schoffel L, Gillessen A. Comparison of two treatment regimens in symptomatically homogenous GERD patient populations: pantoprazole relieves gastrointestinal symptoms significantly better than omeprazole. Gut 2004;53(Suppl VI):A108.
  9. Andersson Т, Bredberg E. Sunzel M. Pharmacokinetics (PK) and effect on pentagas-trin stimulated peak acid output (POA) of omeprazole and its 2 optical isomers, S-omeprazole/esomeprazole and R-omeprazole. Gastroenterology 2000;118:12-20.
  10. Надинская М.Ю. Рабепразол (париет) в лечении гастроэзофагеальной рефлюксной болезни с позиции медицины, основанной на научных доказательствах // Российский журнал гастроэнтерологии гепатологии и колопроктологии. 2004. № 1. С. 9-19.
  11. Старостин Б.Д. Оценка эффективности ингибиторов протонной помпы // Российский журнал гастроэнтерологии гепатологии и колопроктологии. 2003. № 4. С. 21-27.
  12. Richter J, Kahrilas P, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001;96:656-65.
  13. Kahrilas P, Falk G, Johnson D, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000;14:1249-58.
  14. Castell D, Kahrilas P, Richter J, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97:575-83.
  15. Fennerty B, Johanson J, Hwang C, et al. Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2005;21:455-63.
  16. Labenz J, Armstrong D, Lauritsen K, et al. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther 2005;21:739-46.
  17. Shaheen NJ. Is there a Barrett's iceberg? Gаstroenterology 2002;123:636-39.
  18. Shaheen NJ, Crosby MA, Bozymski EM, et al. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gаstroenterology 2000;119:333-38.
  19. Ивашкин В.Т., Трухманов А.С. Современный подход к терапии гастроэзофагеальной рефлюксной болезни во врачебной практике // РМЖ. 2003. № 2. C. 43-48.
  20. DeMeester TR. Clinical biology of the Barrett's metaplasia, dysplasia to carcinoma sequence. Surg. Oncol 2001;10(3):91-102.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies